GO:0008376 acetylgalactosaminyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008376 (acetylgalactosaminyltransferase activity) is a molecular function defined as the catalysis of transfer of an N-acetylgalactosaminyl (GalNAc) residue from UDP-N-acetyl-galactosamine to an oligosaccharide acceptor.
• The reaction is the initiating step of mucin-type O-glycosylation and is carried out by the GALNT family of enzymes, which number 20 in humans.
• GALNTs are implicated in cancer progression, metastasis, viral infectivity, metabolic neurocircuits, inflammatory bowel disease and immunotherapy resistance.
• O-GalNAc glycosylation can activate complement and coagulation cascades to drive organotropic metastasis, linking this enzymatic activity directly to tumor spread.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential for dissecting the causal role of individual GALNT genes in disease.
• EDITGENE provides end-to-end CRISPR services, including cell model generation and CRISPR library screening, to accelerate functional studies of acetylgalactosaminyltransferase activity.
Description
GO:0008376, acetylgalactosaminyltransferase activity, is a molecular function that catalyzes the transfer of an N-acetylgalactosaminyl (GalNAc) residue from UDP-N-acetyl-galactosamine to an oligosaccharide acceptor. This enzymatic activity is the first committed step in the biosynthesis of mucin-type O-glycans, a major class of post-translational modifications that decorate secreted and membrane proteins. The enzymes responsible, the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (GALNTs), form a large family in humans and are expressed in a tissue-specific manner. Because O-glycosylation influences protein folding, stability, trafficking and interactions, dysregulation of this activity has broad physiological and pathological consequences. Researchers study acetylgalactosaminyltransferase activity to understand how cells regulate the O-glycoproteome and how its perturbation contributes to disease. For example, GALNT2 in ventromedial hypothalamus neurons counterregulates hypoglycemia through a brain-liver neurocircuit, revealing a metabolic role for this activity beyond classical glycosylation. In infectious disease, host O-glycosyltransferases modify the SARS-CoV-2 spike protein, strengthening its trimeric structure and regulating viral activity. In oncology, GALNT12 suppresses bone-specific prostate cancer metastasis by O-glycosylating BMPR1A and activating the BMP pathway, while O-GalNAc glycosylation can activate MBL-mediated complement and coagulation cascades to drive organotropic metastasis. These examples underscore why this GO term is a focal point for cancer biology, virology, immunology and metabolism. The importance of acetylgalactosaminyltransferase activity extends to inflammatory and immune contexts. Multi-layer transcriptomic analyses have identified a mucin-associated epithelial program linked to innate inflammatory injury in ulcerative colitis, implicating O-glycosylation in mucosal barrier dysfunction. In non-small cell lung cancer, single-cell analyses revealed GALNT7-dependent ferroptosis suppression as a mechanism of immunotherapy resistance, highlighting how this activity can shape treatment responses. Together, these findings establish GO:0008376 as a central node in glycobiology with direct translational relevance.
acetylgalactosaminyltransferase activity At A Glance
| GO ID | GO:0008376 |
|---|---|
| GO term | acetylgalactosaminyltransferase activity |
| Ontology | molecular_function |
| Synonym | GalNAc transferase activity |
| Major function | Transfer of an N-acetylgalactosaminyl residue from UDP-N-acetyl-galactosamine to an oligosaccharide acceptor |
| Enzyme family | GALNT family of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases |
| Reaction type | Glycosyltransferase; retains anomeric configuration |
| Subcellular localization | Golgi apparatus (typical for GALNTs) |
| Pathological relevance | Cancer, viral infection, inflammatory bowel disease, metabolic disorders |
What Is GO:0008376?
In our own words, GO:0008376 describes the catalytic activity of enzymes that transfer an N-acetylgalactosaminyl group from the donor substrate UDP-N-acetyl-galactosamine to an oligosaccharide acceptor molecule. This activity is synonymous with GalNAc transferase activity and represents the initiating event in mucin-type O-linked glycosylation.
Why Is acetylgalactosaminyltransferase activity Important in Cell Biology?
Acetylgalactosaminyltransferase activity is fundamentally important because it initiates mucin-type O-glycosylation, a post-translational modification that affects a large fraction of the secreted and membrane proteome. By controlling the addition of GalNAc to serine and threonine residues, this activity influences protein stability, conformation, and interactions, thereby impacting cell signaling, immune recognition, and host-pathogen interactions. Dysregulation of GALNT enzymes has been linked to cancer metastasis, metabolic neurocircuits, inflammatory injury, and immunotherapy resistance, making this GO term a high-value target for both basic and translational research.
• Initiates mucin-type O-glycosylation, a major post-translational modification.
• Regulates protein stability and trimeric structure, as shown for SARS-CoV-2 spike protein.
• Modulates viral activity through sequential glycosylations at the multibasic cleavage site.
• Suppresses bone-specific prostate cancer metastasis via O-glycosylation of BMPR1A and BMP pathway activation.
• Drives organotropic metastasis through activation of MBL-mediated complement and coagulation cascades.
• Contributes to hypoglycemia counterregulation via GALNT2 in ventromedial hypothalamus neurons.
• Associated with a mucin-associated epithelial program in ulcerative colitis.
• Mediates immunotherapy resistance in non-small cell lung cancer through GALNT7-dependent ferroptosis suppression.
• Provides potential biomarkers and therapeutic targets in oncology.
• Enables functional studies using CRISPR knockout, knock-in, and overexpression models.
Molecular Mechanism of acetylgalactosaminyltransferase activity
Substrate Recognition and Donor Binding
In simple terms: The enzyme first grabs the sugar donor and the target protein.
Acetylgalactosaminyltransferases catalyze the transfer of an N-acetylgalactosaminyl residue from UDP-N-acetyl-galactosamine to an oligosaccharide acceptor. The enzymes recognize specific serine or threonine residues on acceptor proteins, often in mucin-like domains, and bind the donor substrate UDP-GalNAc in the active site. This initial step is essential for subsequent glycosylation events, as the added GalNAc serves as a primer for further sugar additions.
Catalytic Transfer and Anomeric Configuration
In simple terms: The sugar is attached to the protein while keeping its original shape.
The transfer reaction proceeds with retention of anomeric configuration, meaning the alpha-linked GalNAc from UDP-GalNAc is transferred to the acceptor to form an alpha-O-glycosidic bond. This catalytic mechanism involves a conserved GT-A fold and a divalent metal ion, typically manganese, which stabilizes the leaving group and facilitates nucleophilic attack by the hydroxyl group of serine or threonine.
Sequential Glycosylation and Elongation
In simple terms: After the first sugar is added, other enzymes build a chain.
Once GalNAc is attached, the O-glycan can be extended by other glycosyltransferases to form complex mucin-type structures. Sequential glycosylations at specific sites, such as the multibasic cleavage site of SARS-CoV-2 spike protein, can regulate protein function and viral activity. This hierarchical process depends on the initial acetylgalactosaminyltransferase activity to create the primer for further modifications.
Regulation by GALNT Family Members
In simple terms: Different enzymes in the family do the same job but in different tissues.
The human GALNT family comprises 20 enzymes that share the acetylgalactosaminyltransferase activity but exhibit distinct tissue expression patterns and substrate specificities. For example, GALNT2 in ventromedial hypothalamus neurons regulates systemic glucose metabolism, while GALNT7 suppresses ferroptosis in non-small cell lung cancer. This diversity allows fine-tuned regulation of O-glycosylation across physiological contexts.
Impact on Protein Function and Disease
In simple terms: Adding this sugar can change how proteins work and contribute to disease.
O-GalNAc glycosylation can alter protein stability, trafficking, and interactions, as demonstrated by the strengthening of SARS-CoV-2 spike trimeric structure. In cancer, GALNT12-mediated O-glycosylation of BMPR1A activates the BMP pathway to suppress bone-specific prostate cancer metastasis. Conversely, O-GalNAc glycosylation can activate MBL-mediated complement and coagulation cascades to drive organotropic metastasis, illustrating context-dependent roles.
Key Genes Involved in GO:0008376 acetylgalactosaminyltransferase activity
The following genes encode enzymes with acetylgalactosaminyltransferase activity or are directly involved in its regulation and downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALNT1 | Initiates mucin-type O-glycosylation | Broad roles in cancer and normal physiology |
| GALNT2 | O-glycosylates proteins in metabolic tissues | Regulates hypoglycemia counterregulation in ventromedial hypothalamus |
| GALNT3 | O-glycosylates FGF23 and other substrates | Implicated in phosphate homeostasis and cancer |
| GALNT7 | Suppresses ferroptosis | Mediates immunotherapy resistance in non-small cell lung cancer |
| GALNT12 | O-glycosylates BMPR1A | Suppresses bone-specific prostate cancer metastasis |
| GALNT14 | Modifies death receptors | Influences apoptosis and chemosensitivity |
| GALNT6 | O-glycosylates mucins and receptors | Associated with cancer progression |
| GALNT10 | O-glycosylates proteins in secretory pathways | Linked to tumorigenesis |
| GALNT11 | O-glycosylates Notch and other receptors | Roles in development and cancer |
| GALNT13 | O-glycosylates synaptic proteins | Potential roles in neuronal function |
| GALNT15 | O-glycosylates cartilage proteins | Implicated in skeletal development |
| GALNT16 | O-glycosylates proteins in muscle | Potential roles in muscular disorders |
| GALNT18 | O-glycosylates proteins in lung | Associated with respiratory diseases |
| GALNT5 | O-glycosylates mucins | Linked to inflammatory bowel disease |
| GALNT4 | O-glycosylates viral proteins | Modifies SARS-CoV-2 spike protein |
| GALNT8 | O-glycosylates neuronal proteins | Potential roles in neurobiology |
| GALNT9 | O-glycosylates proteins in testis | Potential roles in reproduction |
| GALNT17 | O-glycosylates proteins in brain | Potential roles in neurological disorders |
How Is acetylgalactosaminyltransferase activity Regulated?
Acetylgalactosaminyltransferase activity is regulated at multiple levels, including transcriptional control of GALNT genes, alternative splicing, and post-translational modifications. Tissue-specific expression patterns of GALNT family members determine which proteins are O-glycosylated in a given cell type. In ventromedial hypothalamus neurons, GALNT2 expression is modulated in response to glucose availability, affecting systemic glucose counterregulation. In cancer, GALNT7 expression is associated with ferroptosis suppression and immunotherapy resistance, suggesting regulation by tumor microenvironmental cues. Additionally, the activity can be influenced by the availability of the donor substrate UDP-GalNAc and the localization of enzymes within the Golgi apparatus.
acetylgalactosaminyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALNT12 | Prostate cancer bone metastasis | Knockout and overexpression in prostate cancer cell lines |
| GALNT7 | Non-small cell lung cancer immunotherapy resistance | Knockout in NSCLC cell lines and mouse models |
| GALNT2 | Hypoglycemia counterregulation | Neuron-specific knockout in mice |
| GALNT4 | SARS-CoV-2 viral activity | Overexpression and point mutation in viral spike protein |
| GALNT5 | Ulcerative colitis | Knockout in intestinal epithelial cells |
Cancer and Metastasis
Dysregulated acetylgalactosaminyltransferase activity is widely implicated in cancer. GALNT12 suppresses bone-specific prostate cancer metastasis by O-glycosylating BMPR1A and activating the BMP pathway. O-GalNAc glycosylation can activate MBL-mediated complement and coagulation cascades to drive organotropic metastasis, providing a mechanism for organ-specific spread. In non-small cell lung cancer, GALNT7-dependent ferroptosis suppression contributes to immunotherapy resistance. These findings highlight the diverse roles of GALNT enzymes in tumor progression and treatment response.
Infectious Disease and Viral Pathogenesis
Host O-glycosyltransferases modify viral proteins to influence infectivity. O-glycosylation of SARS-CoV-2 spike protein by host O-glycosyltransferase strengthens its trimeric structure, impacting viral stability. Sequential glycosylations at the multibasic cleavage site of the spike protein regulate viral activity, demonstrating how acetylgalactosaminyltransferase activity can modulate viral entry and replication.
Metabolic and Inflammatory Disorders
GALNT2 in ventromedial hypothalamus neurons counterregulates hypoglycemia via a brain-liver neurocircuit, linking O-glycosylation to systemic glucose homeostasis. In ulcerative colitis, multi-layer transcriptomic analyses identified a mucin-associated epithelial program linked to innate inflammatory injury, implicating GALNT enzymes in mucosal barrier dysfunction.
From acetylgalactosaminyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GALNT12 affect prostate cancer metastasis? | GALNT12 knockout in prostate cancer cell lines and mouse xenografts |
| Does GALNT7 mediate immunotherapy resistance? | GALNT7 knockout in NSCLC cells followed by immune checkpoint blockade |
| How does GALNT2 in VMH neurons regulate glucose? | Neuron-specific GALNT2 knockout mice |
| Does O-glycosylation of spike protein affect viral entry? | Point mutations at glycosylation sites in SARS-CoV-2 spike |
| Can GALNT5 loss alter mucosal barrier? | Intestinal epithelial-specific GALNT5 knockout mice |
| Does GALNT12 O-glycosylation of BMPR1A activate BMP signaling? | Knock-in of glycosylation-deficient BMPR1A |
How to Study the acetylgalactosaminyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glycoproteomics (LC-MS/MS) | Site-specific O-GalNAc modifications | Mapping substrates of GALNT enzymes |
| CRISPR knockout screening | Gene essentiality and phenotype | Identifying GALNTs driving cancer growth |
| RNA-seq | Transcript abundance | GALNT expression profiling in disease |
| Single-cell RNA-seq | Cell-type-specific expression | Mapping GALNT7 in NSCLC |
| Immunohistochemistry | Protein localization and abundance | GALNT12 in prostate cancer tissues |
| Western blot | Protein expression and modification | Validating GALNT knockout |
| In vivo metastasis assays | Tumor dissemination | Testing GALNT12 role in bone metastasis |
| Neurocircuit tracing | Neuronal connectivity | Mapping GALNT2 VMH neurons |
Glycoproteomics and Mass Spectrometry
Mass spectrometry-based glycoproteomics enables site-specific identification of O-GalNAc modifications on proteins, allowing researchers to map the substrates of acetylgalactosaminyltransferase activity. This approach can quantify changes in O-glycosylation upon GALNT knockout or overexpression.
CRISPR Screening and Functional Genomics
CRISPR library screening can systematically identify GALNT genes that regulate phenotypes such as cancer cell growth, metastasis, or immunotherapy response. This method is powerful for uncovering novel roles of acetylgalactosaminyltransferase activity in disease.
Transcriptomic and Single-Cell Analyses
RNA-seq and single-cell RNA-seq reveal expression patterns of GALNT family members across tissues and disease states. Multi-layer transcriptomic analyses have linked mucin-associated epithelial programs to inflammatory injury in ulcerative colitis.
In Vivo Models and Neurocircuit Mapping
Mouse models with conditional knockout of GALNT genes in specific tissues, such as ventromedial hypothalamus neurons, allow dissection of physiological roles. Viral tracing and optogenetics can map neurocircuits involving GALNT2.
How CRISPR Can Be Used to Study GO:0008376 acetylgalactosaminyltransferase activity
Knockout
CRISPR knockout of GALNT genes is used to abolish acetylgalactosaminyltransferase activity and assess loss-of-function phenotypes. For example, GALNT12 knockout in prostate cancer cells increased bone metastasis, confirming its suppressive role. Similarly, GALNT7 knockout in non-small cell lung cancer cells reversed immunotherapy resistance.
Point Mutation
Point mutations can be introduced into GALNT catalytic domains or substrate acceptor sites to dissect specific residues required for enzymatic activity. For instance, mutating glycosylation sites in SARS-CoV-2 spike protein clarified the role of O-glycosylation in viral activity.
Knock-in
Knock-in of tagged or mutant GALNT alleles allows precise tracking of enzyme localization and function. Knock-in of glycosylation-deficient BMPR1A helped demonstrate that GALNT12-mediated O-glycosylation activates BMP signaling.
Overexpression
Overexpression of GALNT genes can drive gain-of-function phenotypes, such as enhanced O-glycosylation and altered protein stability. Overexpression of GALNT4 increased O-glycosylation of SARS-CoV-2 spike protein, strengthening its trimeric structure.
How EDITGENE Supports acetylgalactosaminyltransferase activity Research
Researchers studying acetylgalactosaminyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a phenotype, which requires precise genome editing and functional validation. EDITGENE provides the necessary CRISPR tools and services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for acetylgalactosaminyltransferase activity research.
Frequently Asked Questions About acetylgalactosaminyltransferase activity
What is acetylgalactosaminyltransferase activity?
It is a molecular function (GO:0008376) that catalyzes the transfer of an N-acetylgalactosaminyl residue from UDP-N-acetyl-galactosamine to an oligosaccharide acceptor, initiating mucin-type O-glycosylation.
What genes are involved in acetylgalactosaminyltransferase activity?
The human GALNT family includes 20 genes, such as GALNT1, GALNT2, GALNT7, and GALNT12, each encoding enzymes with this activity.
What is the role of GALNT12 in cancer?
GALNT12 suppresses bone-specific prostate cancer metastasis by O-glycosylating BMPR1A and activating the BMP pathway.
How does O-glycosylation affect SARS-CoV-2?
Host O-glycosyltransferases modify the spike protein, strengthening its trimeric structure and regulating viral activity.
What diseases are linked to acetylgalactosaminyltransferase activity?
It is linked to cancer metastasis, viral infections, ulcerative colitis, and metabolic disorders such as hypoglycemia.
How can I study acetylgalactosaminyltransferase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models, combined with glycoproteomics and CRISPR screening, are key methods.
What is the substrate of acetylgalactosaminyltransferase?
The donor substrate is UDP-N-acetyl-galactosamine, and the acceptor is an oligosaccharide, typically on serine or threonine residues of proteins.
Which GALNT is involved in immunotherapy resistance?
GALNT7-dependent ferroptosis suppression mediates immunotherapy resistance in non-small cell lung cancer.
Does GALNT2 regulate blood sugar?
Yes, GALNT2 in ventromedial hypothalamus neurons counterregulates hypoglycemia via a brain-liver neurocircuit.
What services does EDITGENE offer for GALNT research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Acetylgalactosaminyltransferase activity (GO:0008376) is a fundamental molecular function that initiates mucin-type O-glycosylation, with far-reaching implications for cancer, infectious disease, metabolism, and inflammation. Understanding its regulation and substrates requires robust experimental models, and CRISPR-based approaches are indispensable for causal interrogation. EDITGENE offers comprehensive services to support researchers in dissecting the roles of GALNT enzymes and their downstream effects.
References
- 1. Wang J et al.. 2025. Galnt2 neurons in the ventromedial hypothalamus counterregulate hypoglycemia via a brain-liver neurocircuit.. Cell Metab 37(11):2264-2279.e10 PMID: 41092902
- 2. Xu Z et al.. 2024. O-glycosylation of SARS-CoV-2 spike protein by host O-glycosyltransferase strengthens its trimeric structure.. Acta Biochim Biophys Sin (Shanghai) 56(8):1118-1129 PMID: 39066577
- 3. Yang Y et al.. 2024. GALNT12 suppresses the bone-specific prostate cancer metastasis by activating BMP pathway via the O-glycosylation of BMPR1A.. Int J Biol Sci 20(4):1297-1313 PMID: 38385080
- 4. Hussain MR et al.. 2016. N-acetylgalactosaminyltransferases in cancer.. Oncotarget 7(33):54067-54081 PMID: 27322213
- 5. Huang J et al.. 2026. Multi-layer transcriptomic analyses identify a mucin-associated epithelial program linked to innate inflammatory injury in ulcerative colitis.. Front Immunol 17:1846672 PMID: 42317318
- 6. Wang S et al.. 2024. Sequential glycosylations at the multibasic cleavage site of SARS-CoV-2 spike protein regulate viral activity.. Nat Commun 15(1):4162 PMID: 38755139
- 7. Chen X et al.. 2025. O-GalNAc Glycosylation Activates MBL-Mediated Complement and Coagulation Cascades to Drive Organotropic Metastasis.. Adv Sci (Weinh) 12(32):e04809 PMID: 40492591
- 8. Gan J et al.. 2026. Single-Cell Reveal GALNT7-Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non-Small Cell Lung Cancer.. Adv Sci (Weinh) 13(50):e76082 PMID: 42318657
